✦ LIBER ✦

Loss of Treatment Response to Infliximab Maintenance Therapy in Crohn's Disease: A Payor Perspective

✍ Scribed by Eric Qiong Wu; Parvez M. Mulani; Andrew Peng Yu; Jackson Tang; Paul F. Pollack

Book ID: 109078795
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 196 KB
Volume: 11
Category: Article
ISSN: 1098-3015
DOI: 10.1111/j.1524-4733.2008.00335.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical trial: impact of prior inflixim

Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease

✍ S. B. Hanauer; J. Panes; J.-F. Colombel; R. Bloomfield; S. Schreiber; W. J. Sand 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB

Adalimumab maintenance therapy for Crohn

Adalimumab maintenance therapy for Crohn’s disease with intolerance or lost response to infliximab: an open-label study

✍ L. PEYRIN-BIROULET; C. LACLOTTE; M.-A. BIGARD 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 482 KB

Review article: loss of response to anti

Review article: loss of response to anti-TNF treatments in Crohn’s disease

✍ S. Ben-Horin; Y. Chowers 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 295 KB

Elevated serum IgE prior to acute severe

Elevated serum IgE prior to acute severe infusion reaction during infliximab maintenance therapy in a crohn's disease patient

✍ Shingo Kato; Taisuke Kobayashi; Kazuhito Kani; Hidehiko Takabayashi; Ryuichi Yam 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 1 views

The duration of effect of infliximab mai

The duration of effect of infliximab maintenance treatment in paediatric Crohn’s disease is limited

✍ C. I. De Bie; T. Z. Hummel; A. Kindermann; F. T. M. Kokke; G. M. Damen; C. M. F. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB

Efficacy of infliximab in pediatric Croh

Efficacy of infliximab in pediatric Crohn's disease: A randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy

✍ Frank M. Ruemmele; Alain Lachaux; Jean-Pierre Cézard; Alain Morali; Chantal Maur 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 2 views

## Background: Infliximab (ifx) is efficacious in inducing remission in severe forms of pediatric crohn's disease (cd). adult studies indicate that ifx is also safe and well tolerated as maintenance therapy. the present study aimed to evaluate in a prospective manner the efficacy and safety of ifx